Missling, Christopher U.

A precision medicine framework using artificial intelligence for the identification and confirmation of genomic biomarkers of response to an Alzheimer's disease therapy: Analysis of the blarcamesine (ANAVEX2‐73) Phase 2a clinical study

Hampel, H., Williams, C., Etcheto, A., Goodsaid, F., Parmentier, F., Sallantin, J., Kaufmann, W. E., Missling, C. U., & Afshar, M. (2020) · Alzheimer's & Dementia: Translational Research & Clinical Interventions

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 84

ANAVEX®2-73 (blarcamesine), a Sigma-1 receptor agonist, ameliorates neurologic impairments in a mouse model of Rett syndrome

Kaufmann, W. E., Sprouse, J., Rebowe, N., Hanania, T., Klamer, D., & Missling, C. U. (2019) · Pharmacology Biochemistry and Behavior

Genetics and Neurodevelopmental DisordersPharmacological Receptor Mechanisms and Effects

Cited by 54

Effects of the sigma-1 receptor agonist blarcamesine in a murine model of fragile X syndrome: neurobehavioral phenotypes and receptor occupancy

Reyes, S. T., Deacon, R. M. J., Guo, S. G., Altimiras, F. J., Castillo, J. B., van der Wildt, B., Morales, A. P., Park, J. H., Klamer, D., Rosenberg, J., et al. (2021) · Scientific Reports

Genetics and Neurodevelopmental DisordersPharmacological Receptor Mechanisms and Effects

Cited by 22

P1‐046: New Exploratory Alzheimer’S Drug Anavex 2‐73: Dose Dependent Clinical Cognitive Improvement Observed in Mini Mental State Examination (MMSE) and Other Cognitive Markers in a Phase 2A Study in Mild‐to‐Moderate Alzheimer’s Patients

Macfarlane, S., Maruff, P., Cecchi, M., Moore, D., Zografidis, T., & Missling, C. (2016) · Alzheimer's & Dementia

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 3